Hedge Fund - Baker Bros. Advisors

In a new filing with the SEC, Julian Baker and Felix Baker’s Baker Bros. Advisors revealed new stake in Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

Julian Baker and Felix Baker’s hedge fund, Baker Bros. Advisors, has recently tweaked its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Synageva Biopharma Corp (NASDAQ:TRMS).

Julian Baker and Felix Baker's Baker Bros. Advisors have disclosed in a new filing with the SEC adding approximately 4,100 shares to their stake in Genomic Health, Inc. (NASDAQ:GHDX).

Julian and Felix Baker's Baker Bros. Advisors has decreased its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,521 shares, from 1,130,317 shares revealed as held earlier.

Julian Baker and Felix Baker have increased their exposure to Seattle Genetics, Inc. (NASDAQ:SGEN) even higher.

Julian Baker and Felix Baker are betting big on Seattle Genetics, Inc. (NASDAQ:SGEN). In a recent Form 4 filing with the Securities and Exchange Commission, their fund, Baker Bros.

Julian and Felix Baker and their hedge fund, Baker Bros. Advisors, reported slicing their exposure at Incyte Corporation (NASDAQ:INCY) to 19.53 million shares, from some 30.20 million held earlier.

Julian and Felix Baker's hedge fund, Baker Bros. Advisors, now holds around 4.4 million shares of Viropharma Inc (NASDAQ:VPHM), a newly amended filing with the SEC has revealed. Baker Bros.

In a couple 13D filings with the SEC, Julian and Felix Baker's Baker Bros. Advisors reported a 19.9% stake in Mirati Therapeutics, Inc.